BioTuesdays

Category - Feature

Concert starts multiple dose trial with CF drug

By Len Zehr Concert Pharmaceuticals (NASDAQ:CNCE), which is modifying known drugs with its deuterium technology, last week initiated a multiple ascending dose Phase 1 trial with healthy volunteers of its next generation...

Viking Therapeutics to complete two POC trials in 2016

By Len Zehr Viking has successfully completed three Phase 1 studies with VK5211, including a 21-day ascending dose study. Viking Therapeutics (NASDAQ:VKTX) expects to complete two proof-of-concept Phase 2 trials in 2016...

CRH Medical to consolidate GI anesthesia market

By Len Zehr With four acquisitions and a joint venture under its belt over the past 10 months, CRH Medical (NYSE MKT:CRHM; TSX:CRH) is in talks to continue consolidating the large and fragmented market of...

In conversation with Arun Menawat

As president and CEO of Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ), Arun Menawat has led the company through a strategic transformation this year into a direct sales company from one originally dependent on partners to...

In conversation with Gagan Gill

By Len Zehr As CEO of closely-held SIGMA Surgical, an upstart data-analytics company, Gagan Gill has a passion for entrepreneurial adventure and startup culture. After stints in sales and marketing in the medical...

In conversation with Geoffrey Hamilton-Fairley

As CEO of closely-held Oncimmune, an early cancer diagnostic company in Britain, Geoffrey Hamilton-Fairley has had a personal commitment to cancer detection. His father was the first medical oncologist in the UK and an...